

Certificate of Analysis

PhKy1, active (Recombinant enzyme expressed in Sf21 insect cells)

Item # 16-018, 16-018-K, 16-018M

Parent Lot # WAF0020

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialing runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialing run.

Product Description: N-terminal GST-tagged, recombinant, human PhKy1 full length expressed by baculovirus in Sf21 insect cells. Purified using glutathione agarose.

Purity 37% by SDS-PAGE and Coomassie blue staining. MW = 72kDa.

Specific Activity (Parent lot# WAF0020): 63U/mg, where one unit of PhKy1 activity is defined as 1nmol phosphate incorporated into 250µM KKLNRTLSFAEPG per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 0.44mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 8.55–110ng of this lot of enzyme phosphorylated 250µM KKLNRTLSFAEPG in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as PhKy1 with the translated sequence listed on page three.



SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3µg of PhKy1, active.

Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

- 1. 5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
- 2. KKLNRTL SFAEPG:** Use at a final assay concentration of 250µM. Prepare a 2.5mM stock and add 2.5µl of stock per assay point.
- 3. PhKy1, active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 8.55–110ng per assay point.
- 4. [γ -³³P]ATP:** 2.5 x MgAc/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required).

Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer per assay to wells.
2. Add 2.5µl of KKLNRTL SFAEPG.
3. Add **2.5µl (8.55–110ng) PhKy1, active.**
4. Add 5.0µl of dH₂O.
5. Add 10µl of diluted [γ -³³P]ATP mixture.
6. Incubate for 30 minutes at 30°C.
7. Stop the reaction by adding 5µl of 3% phosphoric acid.
8. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

PhKy1, active Sequence Information

Protein	Human PhKy1
Tags	N-terminal GST
Native sequence	M230 of the recombinant protein is equivalent to M1 of human PhKy1
Accession number	GenBank NM_006213.2

Recombinant PhKy1 amino acid sequence:

```

1  MSPILGYWKI  KGLVQPTRLL  LEYLEEKYEE  HLYERDEGDK  WRNKKFELGL  EFPNLPYYID
61  GDVKLTQSMA  IIRYIADKHN  MLGGCPKERA  EISMLEGAVL  DIRYGVSRIA  YSKDFETLKV
121 DFLSKLPEML  KMFEDRLCHK  TYLNGDHVTH  PDFMLYDALD  VVLYMDPMCL  DAFPKLVCFK
181 KRIEAIQID  KYLKSSKYIA  WPLQGWQATF  GGGDHPPKSD  LVPRGSKEFM  TRDEALPDSH
241 SAQDFYENY  PKEILGRGVS  SVVRCIHKP  TSQEYAVKVI  DVTGGGSFSP  EEVRELREAT
301 LKEVDILRKV  SGHPNIIQLK  DTYETNTFFF  LVFDLMKRGE  LFDYLTEKVT  LSEKETRKIM
361 RALLEVICTL  HKLNIVHRDL  KPENILLDDN  MNIKLTDFGF  SCQLEPGERL  REVCCTPSYL
421 APEIIECSMN  EDHPGYGKEV  DMWSTGVIMY  TLLAGSPFFW  HRKQMLMLRM  IMSGNYQFGS
481 PEWDDYSDTV  KDLVSRFLV  QPQNRYTAE  ALAHPFFQY  LVEEVRHFSP  RGKFKVIALT
541 VLASVRIYQ  YRRVKPVTRE  IVIRDPYALR  PLRRLIDAYA  FRIYGHVVK  GQQQNRAALF
601 ENTPKAVLLS  LAEDY

```

Recombinant PhKy1 nucleotide sequence:

```

1  atgtccccta  tactaggtta  ttggaaaatt  aagggccttg  tgcaaccac  tgcacttctt
61  ttggaatatc  ttgaagaaaa  atatgaagag  catttgatat  agcgcgatga  aggtgataaa
121  tggcgaaaca  aaaagtttga  attgggtttg  gagtttccca  atcttcctta  ttatatgat
181  ggtgatgta  aattaacaca  gtctatggcc  atcatagctt  atatactga  caagcacaa
241  atgttgggtg  ttgtccaaa  agagcgtgca  gagatttcaa  tgcttgaagg  agcggttttg
301  gatattagat  acggtgtttc  gagaattgca  tatagtaaag  actttgaaac  tctcaaagtt
361  gattttctta  gcaagctacc  tgaaatgctg  aaaatgttcg  aagatcgttt  atgtcataaa
421  acatatatta  atggtgatca  tgtaaccat  cctgacttca  tgttgatatga  cgctcttgat
481  gttgttttat  acatggaccc  aatgtgcctg  gatgcgttcc  caaaattagt  ttgttttaaa
541  aaacgtattg  aagctatccc  acaaattgat  aagtacttga  aatccagcaa  gtatatagca
601  tggcctttgc  agggctggca  agccacgttt  ggtggtggcg  accatcctcc  aaaatcggat
661  ctggttccgc  gtggatccaa  ggaattcatg  acccgggacg  aggcactgcc  ggactctcat
721  tctgcacagg  acttctatga  gaattatgag  cccaaagaga  tcctgggcag  gggcggttagc
781  agtgtggtca  ggcgatgcat  ccacaagccc  acgagccagg  agtacgccgt  gaaggtcatc
841  gacgtcaccg  gtggaggcag  cttcagcccg  gaggaggtgc  gggagctgcg  agaagccacg
901  ctgaaggagg  tggacatcct  gcgcaaggtc  tcagggcacc  ccaacatcat  acagctgaag
961  gacacttatg  agaccaacac  tttcttcttc  ttggtgtttg  acctgatgaa  gagaggggag
1021 ctctttgact  acctcactga  gaaggtcacc  ttgagtgaga  aggaaaccag  aaagatcatg
1081 cgagctctgc  tggaggtgat  ctgcaccttg  cacaactca  acatcgtgca  ccgggacctg
1141 aagcccgaga  acattctctt  ggatgacaac  atgaacatca  agctcacaga  ctttggcttt
1201 tcctgccagc  tggagccggg  agagaggtct  cgagaggtct  gcgggacccc  cagttacctg
1261 gccctggaga  ttatcgagtg  ctccatgaat  gaggaccacc  cgggctacgg  gaaagaggtg
1321 gacatgtgga  gcaactggcg  catcatgtac  acgctgctgg  cgggctcccc  gcccttctgg
1381 caccggaagc  agatgctgat  gctgaggatg  atcatgagcg  gcaactacca  gtttggctcg
1441 cccgagtggg  atgattactc  ggacaccgtg  aaggacctgg  tctcccgatt  cctgggtggtg
1501 caaccccaga  accgctacac  agcggaagag  gccttggcac  accccttctt  ccagcagtac
1561 ttggtggagg  aagtgcggca  cttcagcccc  cgggggaagt  tcaaggtgat  cgctctgacc
1621 gtgctggctt  cagtgcggat  ctactaccag  taccgccggg  tgaagcctgt  gaccggggag

```

Certificate of Analysis

```
1681 atcgtcatcc gagacccta tgccctccgg cctctgcgcc ggctcatcga cgcctacgct
1741 ttccgaatct atggccactg ggtgaagaag gggcagcagc agaaccgggc agcccttttc
1801 gagaacacac ccaaggccgt gtcctctctc ctggccgagg aggactactg a
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 **Eurofins Pharma Discovery Services UK Limited** is an independent member of Eurofins Discovery Services.